Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
106
Registration Number
NCT00006122
Locations
🇫🇷

Hotel Dieu de Paris, Paris, France

🇧🇪

A.Z. St. Jan, Brugge, Belgium

🇦🇹

Innsbruck Universitaetsklinik, Innsbruck, Austria

and more 15 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-02-16
Last Posted Date
2013-01-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00003632
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Phase 2
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2013-09-17
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Registration Number
NCT00002531
Locations
🇩🇪

Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2013-08-07
Lead Sponsor
Hannover Medical School
Registration Number
NCT00002532
Locations
🇩🇪

Medizinische Hochschule Hannover, Hannover, Germany

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2004-02-16
Last Posted Date
2020-07-31
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00004114

Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Phase 3
Completed
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2023-06-22
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
744
Registration Number
NCT00002868
Locations
🇬🇧

Royal Infirmary, Glasgow, Scotland, United Kingdom

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Phase 3
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Target Recruit Count
800
Registration Number
NCT00002869
Locations
🇬🇧

Western General Hospital, Edinburgh, Scotland, United Kingdom

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2004-02-12
Last Posted Date
2023-09-01
Lead Sponsor
University of Nebraska
Target Recruit Count
44
Registration Number
NCT00007852
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

First Posted Date
2004-02-11
Last Posted Date
2013-01-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT00077181
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2004-02-11
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
31
Registration Number
NCT00077116
Locations
🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

🇧🇪

AZ Sint-Jan, Brugge, Belgium

🇧🇪

H. Hartziekenhuis - Roeselaere., Roeselare, Belgium

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy